Wilson Sonsini is pleased to present the latest edition of The Life Sciences Report. This issue features an interview with Foresight Diagnostics co-founder and CEO Jake Chabon conducted by Matthew Meyer, the firm’s Chief Business Advisor for Life Sciences; an article on recent pharmaceutical antitrust developments and expectations for 2022; and a piece on life sciences venture financings in which firm clients participated across the second half of 2020 and the first half of 2021, as well as an article on the firm’s newly launched Salt Lake City office. In addition, the publication includes a discussion of the Genus v. FDA decision clarifying that products meeting both “drug” and “device” definitions must be regulated as devices; an article on the FDA’s regulatory framework for innovator drug products and public disclosures—and what it means for patent strategies; and a summary of select recent life sciences client highlights and upcoming events.

Please click here to read the publication.